Ryuji Morizane,
Assistant Professor,
Harvard Medical School; Visiting Scholar, Wyss Institute
Dr. Morizane is a Principal Investigator at Massachusetts General Hospital, an Assistant Professor at Harvard Medical School, an Affiliated Faculty at Harvard Stem Cell Institute, and a Visiting Scholar at Wyss Institute. He has pioneered research in stem cell differentiation and kidney organoids. He directs research groups focused on kidney regenerative medicine, genome editing in stem cells, and kidney disease modeling. His research has been recognized internationally, and he has received various awards including NIH Director’s New Innovator Award in 2019.
Recreating Kidney Organogenesis in vitro with Human Pluripotent Stem Cells
Wednesday, 19 August 2020 at 14:00
Add to Calendar ▼2020-08-19 14:00:002020-08-19 15:00:00Europe/LondonRecreating Kidney Organogenesis in vitro with Human Pluripotent Stem CellsMulti-Cellular Engineered Living Systems Summit in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
We have developed an efficient, chemically defined protocol for
differentiating human pluripotent stem cells into multipotent nephron
progenitor cells (NPCs) that can form kidney organoids. By
recapitulating metanephric kidney development in vitro we generate SIX2+SALL1+WT1+PAX2+
NPCs with 80-90% efficiency within 8-9 days of differentiation. NPCs
form kidney organoids containing epithelial nephron-like structures
expressing markers of podocytes, proximal tubules, loops of Henle and
distal nephrons in an organized, continuous arrangement that resembles
the nephron in vivo. The organoids express genes reflecting many
transporters seen in adult metanephric-derived kidney, enabling
assessment of transporter-mediated drug nephrotoxicity. Stromal cells
are also generated with the presence of PDGFRBeta+ fibroblasts/pericytes, and CD31+
endothelial cells. This kidney differentiation system can be used to
study mechanisms of human kidney development. Repetitive injury to
tubular cells causes interstitial fibroblast expansion with
characteristics of myofibroblasts, indicating kidney organoids can be
used to model kidney fibrosis in vitro. Polycystic kidney disease (PKD)
patient-derived organoids exhibit cystic phenotypes. Hence the generated
kidney organoids are effective tools to study genetic disorders of the
kidney as well as mechanisms of kidney injury and fibrosis.
Microphysiological platforms in vitro facilitate kidney organoid
vascularization and maturation, which may lead to the development of
functional bioengineered kidneys in the future.
Add to Calendar ▼2020-08-19 00:00:002020-08-19 00:00:00Europe/LondonMulti-Cellular Engineered Living Systems SummitMulti-Cellular Engineered Living Systems Summit in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2020-08-19 14:00:002020-08-19 15:00:00Europe/LondonRecreating Kidney Organogenesis in vitro with Human Pluripotent Stem CellsMulti-Cellular Engineered Living Systems Summit in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com
